A Phase 1 interventional study of NH102 and Placebo in Depression, sponsored by Jiangsu Nhwa Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Jiangsu Nhwa Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 358 studies in Depression with a site in China — 119 open to participants now, 138 under way, 3 of them phase 3. Depression · China.
Among the 358 studies in Depression with a site in China, this one is the 256th largest by enrollment of the 284 interventional ones that give a count, is one of 34 that started in 2022, is one of 15 in phase 1, and was the 310th registered.
8,595 studies on the registry are indexed under Depression; 1,728 are open to participants now.
Browse Depression studies →119 of the 358 studies in Depression with a site in China are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in China, United States, Australia and 12 more countries
Ages 18–75
Xidian University · Sites in China
Ages 18–30 · Healthy volunteers
Peking University · Sites in China
Ages 18–50
Tianjin Medical University · Sites in China
Ages 18–90 · Healthy volunteers
Moon (Guangzhou) Biotechnology Co., Ltd. · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,090 Depression studies recruiting now, 470 (43%) set no upper age limit and 520 (48%) stop at 75 or younger; 203 take children under 18; 311 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
358 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 20 · Phase 3 13 · Phase 4 24
First in 2006; this study’s year is marked. 34 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 81 across 7,074 interventional studies indexed under Depression.
Median enrollment 129 across the 284 interventional studies, 306 across the 74 observational. Of the 140 that completed or were terminated, 9 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 358 have an industry lead sponsor. The 10 most frequent:
Jiangsu Nhwa Pharmaceutical Co., Ltd. is the lead sponsor of 8 studies on the registry; none are open to participants now.
Jiangsu Nhwa Pharmaceutical Co., Ltd. has 2 studies filed under Depression — fewer than ten, so there is no comparison to draw.
43 of the studies in Depression with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07485595Phase 3Tasly Pharmaceutical Group Co., LtdA Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression | 2026-12-31 |
| NCT07738809Capital University of Physical Education and Sports, ChinaEffects of Exercise Intervention on Sleep Quality and Emotional Problems in College Students With Depressive Symptoms | 2026-11 |
| NCT07179913The First Hospital of Jilin UniversityThe Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression | 2026-11-20 |
| NCT07247968Min SuSubanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study | 2026-11-20 |
| NCT07282366Jian-Jun OuVideo Intervention to Reduce Depression-related Stigma Among Adolescents | 2026-11-20 |
Add all 43 to your calendar (.ics) → With an account.
Among the 358 studies in Depression with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of NH102 when administered as multiple oral dose at escalating dose levels in healthy participants.
The drug being tested in this study is called NH102. NH102 is being tested to treat people who have depression. This study will look at the safety, tolerability and PK of NH102 in healthy participants.
The study may enroll up to 30-40 participants. Participants will be randomly assigned within each cohort to receive NH102 or placebo which will remain undisclosed to the participants and study doctor during the study (unless there is an urgent medical need). The study consists of four dose groups: 3 mg (fixed dose), 10 mg (fixed dose), 15 mg (starting at 6 mg, then escalated to 10 mg, and finally to 15 mg), and 20 mg (starting at 10 mg, then escalated to 15 mg, and finally to 20 mg). Each group enrolls 10 subjects, with 8 receiving NH102 and 2 receiving placebo. For the third and fourth dose groups (15 mg and 20 mg) that follow a titration dosing regimen, each includes 2 sentinel subjects (both male). The two sentinel subjects may be dosed simultaneously. Only after both sentinel subjects complete all 17 doses (with a single dose administered on Day 9) and are observed for at least 24 hours, along with preliminary confirmation of safety, may the remaining subjects in the same dose group proceed with dosing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NH102 3mg or NH102 placebo-matching, tablet, orally, bid (at approximately 8:00 AM and 8:00 PM). The morning doses on D1 and D7 (around 8:00 AM) are to be given under fasting conditions. A total of 13 consecutive doses are administered. For fasting doses: fast for at least 10 hours before dosing, fast for 4 hours after dosing, and no water intake 1 hour before and 1 hour after dosing.
Drug: NH102 · Drug: Placebo
NH102 10mg or NH102 placebo-matching, tablet, orally, bid (at approximately 8:00 AM and 8:00 PM). The morning doses on D1 and D7 (around 8:00 AM) are to be given under fasting conditions. A total of 13 consecutive doses are administered. For fasting doses: fast for at least 10 hours before dosing, fast for 4 hours after dosing, and no water intake 1 hour before and 1 hour after dosing.
Drug: NH102 · Drug: Placebo
NH102 6/10/15 mg or NH102 placebo-matching, tablet, orally, bid (at approximately 8:00 AM and 8:00 PM). Days 1-2: 6 mg, bid; Days 3-5: 10 mg, bid; Days 6-9: 15 mg, bid (administered only once on Day 9), for a total of 17 consecutive doses. The morning doses on D1 and D9 (around 8:00 AM) are to be given under fasting conditions. For fasting doses: fast for at least 10 hours before dosing, fast for 4 hours after dosing, and no water intake 1 hour before and 1 hour after dosing.
Drug: NH102 · Drug: Placebo
NH102 10/15/20 mg or NH102 placebo-matching, tablet, orally, bid (at approximately 8:00 AM and 8:00 PM). Days 1-2: 10 mg, bid; Days 3-5: 15 mg, bid; Days 6-9: 20 mg, bid (administered only once on Day 9), for a total of 17 consecutive doses. The morning doses on D1 and D9 (around 8:00 AM) are to be given under fasting conditions. For fasting doses: fast for at least 10 hours before dosing, fast for 4 hours after dosing, and no water intake 1 hour before and 1 hour after dosing.
Drug: NH102 · Drug: Placebo
tables orally
tables orally
Number of participants with adverse events
Time frame: Baseline up to Day 9 ( the 3 mg and 10mg dose groups) or Day 10 (the 15 mg and 20 mg dose groups)
Number of participants with change in laboratory parameters following treatment administration
The laboratory parameters include hematology, clinical chemistry, coagulation and urinalysis.
Time frame: Baseline up to Day 9 ( the 3 mg and 10mg dose groups) or Day 10 (the 15 mg and 20 mg dose groups)
Number of participants with change in vital sign measurements following treatment adminstration
The items of vital sign include blood pressure, heart rate, body temperature and respiratory rate.
Time frame: Baseline up to Day 9 ( the 3 mg and 10mg dose groups) or Day 10 (the 15 mg and 20 mg dose groups)
Number of participants with change in physical examination following treatment administration
Time frame: Baseline up to Day 9 ( the 3 mg and 10mg dose groups) or Day 10 (the 15 mg and 20 mg dose groups)
Number of participants with change in 12-lead ECG following treatment administration
Time frame: Baseline up to Day 9 ( the 3 mg and 10mg dose groups) or Day 10 (the 15 mg and 20 mg dose groups)
Number of participants with change in Columbia-suicide severity rating scale (C-SSRS) score
Time frame: Baseline up to Day 9 ( the 3 mg and 10mg dose groups) or Day 10 (the 15 mg and 20 mg dose groups)
Plasma PK parameters-Maximum plasma concentration (Cmax) after single-dose administration
Time frame: From pre-dose to 12 hours (before the second administration on Day 1)
Plasma PK Parameters-Time for maximum plasma concentration (Tmax)
Time frame: From pre-dose to 12 hours (before the second administration on Day 1), and from pre-dose on Day 7 to 48 hours (Day 9) for the 3 mg and 10 mg dose groups, or from pre-dose on Day 9 to 24 hours (Day 10) for the 15 mg and 20 mg dose groups.
Plasma PK Parameters-Area Under Curve from zero to 24 hours (AUC0-12h)
Time frame: From pre-dose to 12 hours (before the second administration on Day 1)
Plasma PK Parameters-Maximum observed drug concentration at steady state (Cmax,ss)
Time frame: From pre-dose on Day 7 to 48 hours (Day 9) for the 3 mg and 10 mg dose groups, or from pre-dose on Day 9 to 24 hours (Day 10) for the 15 mg and 20 mg dose groups.
Plasma PK Parameters-Minimum observed drug concentration at steady state (Cmin,ss)
Time frame: From pre-dose on Day 7 to 48 hours (Day 9) for the 3 mg and 10 mg dose groups, or from pre-dose on Day 9 to 24 hours (Day 10) for the 15 mg and 20 mg dose groups.
Plasma PK-Parameters-Average drug concentration at steady state (Cav,ss)
Time frame: From pre-dose on Day 7 to 48 hours (Day 9) for the 3 mg and 10 mg dose groups, or from pre-dose on Day 9 to 24 hours (Day 10) for the 15 mg and 20 mg dose groups.
Plasma PK Parameters-Area Under Curve from time zero to the last time point with a measurable concentration (AUC0-t)
Time frame: From pre-dose on Day 7 to 48 hours (Day 9) for the 3 mg and 10 mg dose groups, or from pre-dose on Day 9 to 24 hours (Day 10) for the 15 mg and 20 mg dose groups.
Plasma PK Parameters-Area Under Curve from zero to infinity (AUC0-∞)
Time frame: From pre-dose on Day 7 to 48 hours (Day 9) for the 3 mg and 10 mg dose groups, or from pre-dose on Day 9 to 24 hours (Day 10) for the 15 mg and 20 mg dose groups.
Plasma PK Parameters-Area Under Curve over a dosing interval at steady state (AUCss)
Time frame: From pre-dose on Day 7 to 48 hours (Day 9) for the 3 mg and 10 mg dose groups, or from pre-dose on Day 9 to 24 hours (Day 10) for the 15 mg and 20 mg dose groups.
Plasma PK Parameters-Apparent total body clearance at steady state after extravascular administration (CLss/F)
Time frame: From pre-dose on Day 7 to 48 hours (Day 9) for the 3 mg and 10 mg dose groups, or from pre-dose on Day 9 to 24 hours (Day 10) for the 15 mg and 20 mg dose groups.
Plasma PK Parameters-Trough drug concentration (Ctrough)
Time frame: From pre-dose on Day 7 to 48 hours (Day 9) for the 3 mg and 10 mg dose groups, or from pre-dose on Day 9 to 24 hours (Day 10) for the 15 mg and 20 mg dose groups.
Plasma PK Parameters-Degree of Fluctuation (DF)
Time frame: From pre-dose on Day 7 to 48 hours (Day 9) for the 3 mg and 10 mg dose groups, or from pre-dose on Day 9 to 24 hours (Day 10) for the 15 mg and 20 mg dose groups.
Plasma PK Parameters-Terminal elimination rate constant (λz)
Time frame: From pre-dose on Day 7 to 48 hours (Day 9) for the 3 mg and 10 mg dose groups, or from pre-dose on Day 9 to 24 hours (Day 10) for the 15 mg and 20 mg dose groups.
Plasma PK Parameters-Relative bioavailability based on AUC [Ra(AUC)]
Time frame: From pre-dose on Day 7 to 48 hours (Day 9) for the 3 mg and 10 mg dose groups, or from pre-dose on Day 9 to 24 hours (Day 10) for the 15 mg and 20 mg dose groups.
Plasma PK Parameters-Terminal half-life (t1/2z)
Time frame: From pre-dose on Day 7 to 48 hours (Day 9) for the 3 mg and 10 mg dose groups, or from pre-dose on Day 9 to 24 hours (Day 10) for the 15 mg and 20 mg dose groups.
Plasma PK Parameters-Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)
Time frame: From pre-dose on Day 7 to 48 hours (Day 9) for the 3 mg and 10 mg dose groups, or from pre-dose on Day 9 to 24 hours (Day 10) for the 15 mg and 20 mg dose groups.
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2022 to primary completion in Apr 2023, 13 months.
Of 102 phase 1 interventional studies under Depression, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 54. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NH102
Jiangsu Nhwa Pharmaceutical Co., Ltd.